Baseline Clinical Characteristics and Complement Biomarkers of Patients with C3 Glomerulopathy Enrolled in Two Phase 2 Studies Investigating the Factor D Inhibitor Danicopan — Steven D. Podos (2022) | RDL Network
Baseline Clinical Characteristics and Complement Biomarkers of Patients with C3 Glomerulopathy Enrolled in Two Phase 2 Studies Investigating the Factor D Inhibitor Danicopan
Article 2022 en
Authors
SP
Steven D. Podos
HT
Howard Trachtman
GA
Gerald B. Appel
Abstract
1 min read
Associations among complement biomarkers, kidney function, and kidney histology may add to the current understanding of C3G and assist with the characterization of patients with this heterogenous disease.
Carla Nester, Steven D. Podos, Jonathan Hogan, Gerald B. Appel, Andrew S. Bomback, Koen Bouman, Terry Cook, Erica Daina, Bradley P. Dixon, Craig B. Langman, Liz Lightstone, Jane A. Thanassi, Kara Rice, Mingjun Huang, Samir M. Parikh, Matthew C. Pickering, John Sperati, Howard Trachtman, James A. Tumlin, Jack F.M. Wetzels, Giuseppe Remuzzi
Carla Nester, Gerald B. Appel, Andrew S. Bomback, Koenraad Peter Bouman, H. Terence Cook, Erica Daina, Bradley P. Dixon, Kara Rice, Nader Najafian, James Hoi Po Hui, Steven D. Podos, Craig B. Langman, Liz Lightstone, Samir V. Parikh, Matthew C. Pickering, C. John Sperati, Howard Trachtman, James Tumlin, Aiko P. J. de Vries, Jack F.M. Wetzels, Giuseppe Remuzzi
.webp){kind=small}
Discussion(0)
No comments yet. Be the first to comment.